Clinical trials: Essential,Hypertension
Hypertension (HTN), Hypertension
A Study to Evaluate the Effectiveness and Safety of S-amlodipine-based Monotherapy and Combination Therapy
This study aims to evaluate the effectiveness, safety, and clinical utility as a treatment strategy of the s-amlodipine-based monotherapy, dual combination, and triple combination in patients with hypertension across various…
- Conditions
- Hypertension (HTN), Hypertension, Essential (Primary) Hypertension
- Trial name
- STRIKE (NCT07907822)
- Volunteers
- 4,528 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypertension, Hypertension,Essential
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
- Trial name
- NCT06205628
- Testing
- ADX-850
- Where
- 3 sites in Australia
- Volunteers
- 28 people
- Sponsor
- ADARx Pharmaceuticals, Inc.
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.
Essential Hypertension, Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
- Trial name
- NCT06220773
- Testing
- BR1019A, BR1019B, BR1019C
- Where
- 3 sites in Indonesia, South Korea
- Volunteers
- 276 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Cardiovascular Diseases
Global Paradise System US Post Approval Study
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood…
- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Trial name
- US GPS (NCT06297291)
- Testing
- Paradise Ultrasound Renal Denervation Treatment
- Where
- 46 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- ReCor Medical, Inc.
Essential Hypertension
Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
The aim of this observational study is to monitor the effectiveness of therapy, adherence and safety of a fixed combination of perindopril + amlodipine in patients with essential hypertension.
- Trial name
- NCT07876895
- Testing
- fixed combination of perindopril + amlodipine
- Where
- Bosnia and Herzegovina
- Volunteers
- 600 people
- Sponsor
- Bosnalijek D.D
Hypertension, Hypertension, Systolic
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure…
- Conditions
- Hypertension, Hypertension, Systolic, Hypertension, Essential
- Trial name
- BACKBEAT (NCT06059638)
- Testing
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Where
- 131 sites in United States, Australia and 13 more
- Volunteers
- 316 people
- Sponsor
- Orchestra BioMed, Inc
Essential Hypertension
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.
- Trial name
- NCT07282145
- Testing
- BCD101 Low Dose Liquid Formulation, BCD101 High Dose Liquid Formulation, BCD101 Low + High Dose Liquid Formulation
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bichedam Co., Ltd.
Hypertension, Vascular Diseases
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent.
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases
- Trial name
- RADIANCE-II (NCT03614260)
- Testing
- Paradise Renal Denervation System, Renal Angiogram
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- ReCor Medical, Inc.
Essential Hypertension
Efficacy and Safety of AJU-C52 in Essential Hypertension Patients
A Randomized, Double-blind, Multi-center, Phase III study to evaluate the efficacy and safety of the AJU-C52 compared with the combination of C52R1M in patients with essential Hypertension Patients who have inappropriately…
- Trial name
- NCT06416865
- Testing
- AJU-C52L, AJU-C52, C52R1L, C52R1M
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- AJU Pharm Co., Ltd.
Essential Hypertension
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
- Trial name
- NCT05503953
- Testing
- AGSAVI, AGLS
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Essential Hypertension, Diabetes Mellitus, Type 2
Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes
The purpose of this study is to evaluate safety and efficacy of ATB-1011 and ATB-1012 co-administration in patients with essential hypertension and type II diabetes mellitus
- Trial name
- NCT05573477
- Testing
- ATB-1011, ATB-1012, ATB-1013
- Where
- South Korea
- Volunteers
- 255 people
- Sponsor
- Autotelicbio
Hypertension, Hypertension,Essential
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive…
- Trial name
- RADAR (NCT07083765)
- Testing
- Dehydrated Alcohol Injection, USP
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Ablative Solutions, Inc.
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C
The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia
- Trial name
- NCT06165250
- Testing
- BR1018A, BR1018A-1, BR1018B
- Where
- 2 sites in South Korea
- Volunteers
- 151 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data…
- Trial name
- NCT06604897
- Where
- United States
- Volunteers
- 1,405 people
- Sponsor
- Novartis Pharmaceuticals
High Blood Pressure (& [Essential Hypertension])
Nifedipine Extended-Release in Patients With Mild or Moderate Hypertension
To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult…
- Trial name
- NCT07448506
- Testing
- Treatment with Nifedipine 30 mg Extended-Release (Richmond), Comparator Nifedipine 30 mg Extended-Release
- Where
- Colombia
- Volunteers
- 50 people
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-224
The purpose of this study is to evaluate the efficacy and safety of AD-224
- Trial name
- NCT06291207
- Testing
- AD-224A, AD-224B, AD-224C
- Where
- South Korea
- Volunteers
- 254 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).
- Trial name
- NCT07704684
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Amlodipine Group
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT07704697
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Sacubitril/Allisartan Group
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.